Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03930654
Other study ID # HSC-MS-16-0892
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 13, 2019
Est. completion date December 31, 2021

Study information

Verified date August 2022
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

African American (AA) women are more vulnerable to HIV infection than other women. Truvada, when used as pre-exposure prophylaxis (PrEP), is one of the most effective approaches for HIV prevention; however, PrEP use among AA women remains low and has not responded to traditional interventions. This study proposes for the first time an innovative computer-based motivational intervention, increasing PrEP uptake (iPrEP), which couples motivational messages woven into a traditional survey to raise awareness of risky sex and substance use behaviors.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 31, 2021
Est. primary completion date December 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Current HIV negative status (based on ED' HIV test outcome) - Condomless sex in the last 3 months - Substance use in the last 3 months - HIV testing during ED visit (usual care) - Has a non-emergent health condition - Has a working mobile device with them Exclusion Criteria: - Ineligible for PrEP (see eligibility criteria to the right) - Assigned male at birth - An HIV positive status - Currently taking medication that are known contraindications for PrEP (brand name: Truvada) - Currently on PrEP

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
iPrEP
iPrEP transforms the standard emergency department (ED) visit experience through an intervention presented as a standard assessment that is equipped to: 1) increase knowledge of HIV transmission and 2) provide information on how to reduce an individual's risk for HIV. Women will receive the iPrEP intervention on an iPAD Air tablet device iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument iPrEP uses qualitative themes iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument Scales were modified (in some cases) for cultural competency and tailoring to women
Usual Care
Women will receive usual care Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use Social worker will offer a list of substance abuse treatment referral agencies

Locations

Country Name City State
United States The University of Texas Health Science Center at Houston Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with an increased willingness for pre-exposure prophylaxis (PrEP) uptake Participants will be assessed for social norms and risk. 1 month
Primary Number of participants with an increased willingness for pre-exposure prophylaxis (PrEP) uptake Participants will be assessed for social norms and risk. 3 months
Primary Number of participants with an increased willingness for pre-exposure prophylaxis (PrEP) uptake Participants will be assessed for social norms and risk. 6 months
Secondary Number of participants with decreased high risk sex 1 month
Secondary Number of participants with decreased high risk sex 3 months
Secondary Number of participants with decreased high risk sex 6 months
Secondary Number of participants with decrease in substance use 1 month
Secondary Number of participants with decrease in substance use 3 months
Secondary Number of participants with decrease in substance use 6 months
Secondary Number of participants with a new sexually transmitted disease diagnosis 1 month
Secondary Number of participants with a new sexually transmitted disease diagnosis 3 months
Secondary Number of participants with a new sexually transmitted disease diagnosis 6 months
Secondary Number of participants with HIV seroconversion 1 month
Secondary Number of participants with HIV seroconversion 3 months
Secondary Number of participants with HIV seroconversion 6 months
Secondary iPrEP feasibility and acceptability as assessed by the number of participants who believe that they had more information to make a better decision about being in a PrEP program after completing the survey intervention As part of the survey, participants will be asked if they believe that they had more information to make a better decision about being in a PrEP program after completing the survey intervention. baseline
Secondary iPrEP feasibility and acceptability as assessed by how much participant liked or disliked completing the survey As part of the survey, participants will asked "How much did you like or dislike completing this questionnaire?" and will choose one of the following 5 categorical choices: Liked it, Liked it somewhat, Neither liked nor disliked it, Disliked it somewhat, Disliked it baseline
Secondary iPrEP feasibility and acceptability as assessed by how often participants relied on the survey questions being read aloud to be able to answer them As part of the survey, participants will asked "As you completed this questionnaire, how often did you rely on the questions being read aloud to be able to answer them?" and will choose one of the following 4 categorical choices: For all the questions, For most of the questions, For some of the questions, For none of the questions baseline
Secondary iPrEP feasibility and acceptability as assessed by number of participants who needed help from site staff in order to complete the survey As part of the survey, participants will be asked if they needed help from site staff in order to complete the survey. baseline
Secondary iPrEP feasibility and acceptability as assessed by the kind of help that participants needed from site staff in order to complete the survey As part of the survey, participants will asked "What kind of help did you need? Please check all that apply" and will choose among the following categorical 4 choices: I had to have some of the questions explained to me, I needed help using the iPAD, I needed to have the questionnaire read to me by a staff member, I needed help for a different reason baseline
Secondary iPrEP feasibility and acceptability as assessed by how participants felt about the length of the survey As part of the survey, participants will asked how they felt about the length of the survey and will choose one of the following 3 categorical choices: Too long, Too short, The right length baseline
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2